1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Lung Cancer - Pipeline Review, 2015

Lung Cancer - Pipeline Review, 2015

  • October 2015
  • -
  • Global Data
  • -
  • 285 pages

Lung Cancer - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Lung Cancer - Pipeline Review, 2015" provides an overview of Lung Cancer diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Lung Cancer diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Lung Cancer diagnostic tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Lung Cancer diagnostic tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Lung Cancer diagnostic tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Lung Cancer - Pipeline Review, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 15
2 Introduction 16
2.1 Lung Cancer Overview 16
3 Products under Development 17
3.1 Lung Cancer - Pipeline Products by Stage of Development 17
3.2 Lung Cancer - Pipeline Products by Territory 18
3.3 Lung Cancer - Pipeline Products by Regulatory Path 19
3.4 Lung Cancer - Pipeline Products by Estimated Approval Date 20
3.5 Lung Cancer - Ongoing Clinical Trials 21
4 Lung Cancer - Pipeline Products under Development by Companies 22
4.1 Lung Cancer Companies - Pipeline Products by Stage of Development 22
4.2 Lung Cancer - Pipeline Products by Stage of Development 27
5 Lung Cancer Companies and Product Overview 32
5.1 AandG Pharmaceutical, Inc. Company Overview 32
5.2 Abbott Diagnostics Company Overview 35
5.3 Abcodia Ltd. Company Overview 46
5.4 Aberystwyth University Company Overview 47
5.5 Advanced Marker Discovery, S.L. Company Overview 48
5.6 Advpharma Inc. Company Overview 51
5.7 Almac Diagnostics Limited Company Overview 53
5.8 Armune BioScience, Inc. Company Overview 55
5.9 Aurelium BioPharma Inc. (Inactive) Company Overview 56
5.10 Biocept, Inc. Company Overview 57
5.11 Biodesix Inc. Company Overview 59
5.12 BioMark Diagnostics Inc. Company Overview 60
5.13 BioMark Technologies Inc. Company Overview 63
5.14 BioMarker Strategies, LLC Company Overview 64
5.15 Biomoda, Inc. (Inactive) Company Overview 65
5.16 BioNTech AG Company Overview 68
5.17 BioSystems International Company Overview 69
5.18 BioTime, Inc. Company Overview 70
5.19 Boise State University Company Overview 72
5.20 Cancer Research Technology Limited Company Overview 73
5.21 Cangen Biotechnologies, Inc. Company Overview 74
5.22 Celera Corporation Company Overview 77
5.23 Cellanyx Diagnostics, Inc. Company Overview 79
5.24 CellMax Life Company Overview 80
5.25 CeMines, Inc. Company Overview 81
5.26 Cepheid Company Overview 82
5.27 Ceres Nanosciences, Inc. Company Overview 84
5.28 Cernostics Inc. Company Overview 85
5.29 ChemImage Corporation Company Overview 86
5.30 Chronix Biomedical, Inc. Company Overview 87
5.31 Clarient, Inc. Company Overview 89
5.32 Courtagen Life Sciences, Inc. Company Overview 94
5.33 Dako A/S Company Overview 95
5.34 Dartmouth College Company Overview 97
5.35 DiagnoCure Inc. Company Overview 99
5.36 EDP Biotech Corporation Company Overview 101
5.37 Emory University Company Overview 102
5.38 Epigenomics AG Company Overview 103
5.39 Eventus Diagnostics, Inc. Company Overview 106
5.40 Exact Sciences Corporation Company Overview 107
5.41 Exiqon A/S Company Overview 109
5.42 Exosomics Siena SpA Company Overview 111
5.43 Fina Biotech Company Overview 112
5.44 Fluxion Biosciences, Inc. Company Overview 113
5.45 Forschungszentrum Borstel Company Overview 114
5.46 Gene Express, Inc. Company Overview 115
5.47 GeneCentric Diagnostics, Inc. Company Overview 119
5.48 Genentech, Inc. Company Overview 120
5.49 GenomicTree, Inc. Company Overview 121
5.50 GILUPI Nanomedizin Company Overview 122
5.51 Global Discovery Biosciences Company Overview 123
5.52 GlycoZym Company Overview 124
5.53 HTG Molecular Diagnostics, Inc. Company Overview 125
5.54 ImmunoCellular Therapeutics, Ltd. Company Overview 127
5.55 Insight Genetics, Inc. Company Overview 129
5.56 Institut National de la Sante et de la Recherche Medicale Company Overview 133
5.57 InterGenetics Incorporated Company Overview 134
5.58 IV Diagnostics, Inc. Company Overview 135
5.59 Laboratorios SALVAT S.A. Company Overview 136
5.60 Louisville Bioscience, Inc. Company Overview 137
5.61 Mayo Clinic Company Overview 138
5.62 MDNA Life Sciences, Inc. Company Overview 139
5.63 MDxHealth SA Company Overview 140
5.64 Medical Prognosis Institute A/S Company Overview 144
5.65 MEDITE Cancer Diagnostics, Inc. Company Overview 146
5.66 Memory Dx, LLC Company Overview 148
5.67 Metabolon, Inc. Company Overview 149
5.68 Metanomics Health GmbH Company Overview 150
5.69 MetaStat, Inc. Company Overview 152
5.70 Milagen, Inc. Company Overview 154
5.71 MolecularMD, Corp. Company Overview 155
5.72 Nanopore Diagnostics, LLC Company Overview 156
5.73 Neogenix Oncology, Inc. Company Overview 157
5.74 NEOMICS Co., Ltd. Company Overview 158
5.75 Novel Bio-spectrum Technologies, Inc. Company Overview 159
5.76 Nuvera Biosciences, Inc. Company Overview 160
5.77 Oncolome Diagnostics Inc. Company Overview 161
5.78 Onconome, Inc. Company Overview 162
5.79 On-Q-ity, Inc. (Inactive) Company Overview 163
5.80 OPKO Health, Inc. Company Overview 164
5.81 Orion Genomics LLC Company Overview 166
5.82 OTraces Inc. Company Overview 168
5.83 Oxford Gene Technology Limited Company Overview 169
5.84 PeriRx LLC Company Overview 170
5.85 PleX Diagnostics Company Overview 171
5.86 Precision Biologics, Inc. Company Overview 172
5.87 PreMD Inc. Company Overview 174
5.88 Proplex Technologies, Llc Company Overview 175
5.89 Proteome Sciences Plc Company Overview 177
5.90 Proteomika Company Overview 179
5.91 Quest Diagnostics Incorporated Company Overview 180
5.92 RCP Diagnostics, LLC (Inactive) Company Overview 183
5.93 RiboMed Biotechnologies, Inc. Company Overview 184
5.94 Roche Diagnostics International Ltd. Company Overview 185
5.95 Rosetta Genomics, Ltd. Company Overview 195
5.96 Roswell Park Cancer Institute Company Overview 197
5.97 Siemens Healthcare Diagnostics Inc. Company Overview 198
5.98 Sienna Cancer Diagnostics Ltd Company Overview 201
5.99 Sividon Diagnostics GmbH Company Overview 202
5.100 SomaLogic, Inc. Company Overview 203
5.101 Southern Illinois University Carbondale Company Overview 205
5.102 Syndax Pharmaceuticals, Inc. Company Overview 206
5.103 The Wistar Institute Company Overview 207
5.104 Todos Medical Company Overview 208
5.105 Transgene SA Company Overview 209
5.106 Trinity College Dublin Company Overview 211
5.107 University of Chicago Company Overview 212
5.108 University of Colorado Company Overview 215
5.109 University of South Florida Company Overview 216
5.110 University of Strathclyde Company Overview 218
5.111 US Biomarkers, Inc. Company Overview 220
5.112 Ventana Medical Systems, Inc. Company Overview 221
5.113 Veracyte, Inc. Company Overview 222
5.114 Vigilant Biosciences, Inc. Company Overview 224
5.115 Viomics Inc. Company Overview 225
5.116 VisionGate, Inc. Company Overview 226
5.117 Vitatex Inc. Company Overview 227
5.118 VolitionRX Ltd. Company Overview 229
5.119 XEPTAGEN SpA Company Overview 233
5.120 Zetiq Technologies Ltd. Company Overview 236
6 Lung Cancer- Recent Developments 237
7 Appendix 279
7.1 Methodology 279
7.2 About GlobalData 281
7.3 Contact Us 282
7.4 Disclaimer 282

1.1 List of Tables
Table 1: Lung Cancer - Pipeline Products by Stage of Development 20
Table 2: Lung Cancer - Pipeline Products by Territory 21
Table 3: Lung Cancer - Pipeline Products by Regulatory Path 22
Table 4: Lung Cancer - Pipeline Products by Estimated Approval Date 23
Table 5: Lung Cancer - Ongoing Clinical Trials 24
Table 6: Lung Cancer Companies - Pipeline Products by Stage of Development 25
Table 7: Lung Cancer - Pipeline Products by Stage of Development 30
Table 8: AandG Pharmaceutical, Inc. Pipeline Products and Ongoing Clinical Trials Overview 35
Table 9: Onco 88 - Lung Cancer - Product Status 36
Table 10: Onco 88 - Lung Cancer - Product Description 36
Table 11: OncoStain 88 - Lung Cancer - Product Status 37
Table 12: OncoStain 88 - Lung Cancer - Product Description 37
Table 13: Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 38
Table 14: ACTN4 Companion Diagnostic Assay - Lung Cancer - Product Status 39
Table 15: ACTN4 Companion Diagnostic Assay - Lung Cancer - Product Description 39
Table 16: ALK Companion Diagnostic Assay - Lung Cancer - Product Status 40
Table 17: ALK Companion Diagnostic Assay - Lung Cancer - Product Description 40
Table 18: cMET Companion Diagnostic Assay - Lung Cancer - Product Status 41
Table 19: cMET Companion Diagnostic Assay - Lung Cancer - Product Description 41
Table 20: EML4 Companion Diagnostic Assay - Lung Cancer - Product Status 42
Table 21: EML4 Companion Diagnostic Assay - Lung Cancer - Product Description 42
Table 22: FGFR1 Companion Diagnostic Assay - Lung Cancer - Product Status 43
Table 23: FGFR1 Companion Diagnostic Assay - Lung Cancer - Product Description 43
Table 24: Heregulin Companion Diagnostic Assay - Lung Cancer - Product Status 44
Table 25: Heregulin Companion Diagnostic Assay - Lung Cancer - Product Description 44
Table 26: IGF1R Companion Diagnostic Assay - Lung Cancer - Product Status 45
Table 27: IGF1R Companion Diagnostic Assay - Lung Cancer - Product Description 45
Table 28: MAGE-A3 Companion Lung Cancer Assay - Product Status 46
Table 29: MAGE-A3 Companion Lung Cancer Assay - Product Description 46
Table 30: PIK3CA Companion Diagnostic Assay - Lung Cancer - Product Status 47
Table 31: PIK3CA Companion Diagnostic Assay - Lung Cancer - Product Description 47
Table 32: PRAME Antigen Lung Cancer Assay - Product Status 48
Table 33: PRAME Antigen Lung Cancer Assay - Product Description 48
Table 34: Abcodia Ltd. Pipeline Products and Ongoing Clinical Trials Overview 49
Table 35: Diagnostic Assay - Lung Cancer - Product Status 49
Table 36: Diagnostic Assay - Lung Cancer - Product Description 49
Table 37: Aberystwyth University Pipeline Products and Ongoing Clinical Trials Overview 50
Table 38: Diagnostic Biomarker Test - Lung Cancer - Product Status 50
Table 39: Diagnostic Biomarker Test - Lung Cancer - Product Description 50
Table 40: Advanced Marker Discovery, S.L. Pipeline Products and Ongoing Clinical Trials Overview 51
Table 41: Predictive Diagnostic Test - Lung Cancer - Product Status 52
Table 42: Predictive Diagnostic Test - Lung Cancer - Product Description 52
Table 43: Prognostic Test - Lung Cancer - Product Status 53
Table 44: Prognostic Test - Lung Cancer - Product Description 53
Table 45: Advpharma Inc. Pipeline Products and Ongoing Clinical Trials Overview 54
Table 46: Lung Cancer Prognostic Assay - Product Status 54
Table 47: Lung Cancer Prognostic Assay - Product Description 54
Table 48: Molecular Diagnostic Biomarker - Lung Cancer - Product Status 55
Table 49: Molecular Diagnostic Biomarker - Lung Cancer - Product Description 55
Table 50: Almac Diagnostics Limited Pipeline Products and Ongoing Clinical Trials Overview 56
Table 51: Prognostic Test - Early Stage Lung Cancer - Product Status 57
Table 52: Prognostic Test - Early Stage Lung Cancer - Product Description 57
Table 53: Armune BioScience, Inc. Pipeline Products and Ongoing Clinical Trials Overview 58
Table 54: Diagnostic Test - Lung Cancer - Product Status 58
Table 55: Diagnostic Test - Lung Cancer - Product Description 58
Table 56: Aurelium BioPharma Inc. (Inactive) Pipeline Products and Ongoing Clinical Trials Overview 59
Table 57: Lung Cancer Screening Test - Product Status 59
Table 58: Lung Cancer Screening Test - Product Description 59
Table 59: Biocept, Inc. Pipeline Products and Ongoing Clinical Trials Overview 60
Table 60: MicroRNA Test - Lung Cancer - Product Status 61
Table 61: MicroRNA Test - Lung Cancer - Product Description 61
Table 62: Biodesix Inc. Pipeline Products and Ongoing Clinical Trials Overview 62
Table 63: TAm-Seq NGS Lung Cancer Test - Product Status 62
Table 64: TAm-Seq NGS Lung Cancer Test - Product Description 62
Table 65: BioMark Diagnostics Inc. Pipeline Products and Ongoing Clinical Trials Overview 63
Table 66: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Status 63
Table 67: Metabolomics-based Diagnostic Assay - Lung Cancer - Product Description 63
Table 68: BioMark Diagnostics Inc. - Ongoing Clinical Trials Overview 64
Table 69: Metabolomics-based Diagnostic Assay - Lung Cancer - Clinical Trial with Patented Non-invasive, Urine-based Assay to Measure Response to Treatment for Lung Cancer 65
Table 70: BioMark Technologies Inc. Pipeline Products and Ongoing Clinical Trials Overview 66
Table 71: Biomarker Assay - Lung Cancer - Product Status 66
Table 72: Biomarker Assay - Lung Cancer - Product Description 66
Table 73: BioMarker Strategies, LLC Pipeline Products and Ongoing Clinical Trials Overview 67
Table 74: Ex Vivo Biomarker Test - Lung Cancer - Product Status 67
Table 75: Ex Vivo Biomarker Test - Lung Cancer - Product Description 67
Table 76: Biomoda, Inc. (Inactive) Pipeline Products and Ongoing Clinical Trials Overview 68
Table 77: CyPath Diagnostic Assay - Lung Cancer - Product Status 68
Table 78: CyPath Diagnostic Assay - Lung Cancer - Product Description 68
Table 79: Biomoda, Inc. (Inactive) - Ongoing Clinical Trials Overview 69
Table 80: CyPath Diagnostic Assay - Lung Cancer - Evaluation of The Biomoda CyPath Early Lung Cancer Detection Assay 70
Table 81: CyPath Diagnostic Assay - Lung Cancer - Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer 70
Table 82: BioNTech AG Pipeline Products and Ongoing Clinical Trials Overview 71
Table 83: Lung Cancer Screening Test - Product Status 71
Table 84: Lung Cancer Screening Test - Product Description 71
Table 85: BioSystems International Pipeline Products and Ongoing Clinical Trials Overview 72
Table 86: Diagnostic Test - Lung Cancer - Product Status 72
Table 87: Diagnostic Test - Lung Cancer - Product Description 72
Table 88: BioTime, Inc. Pipeline Products and Ongoing Clinical Trials Overview 73
Table 89: PanC-Dx - Lung Cancer - Product Status 74
Table 90: PanC-Dx - Lung Cancer - Product Description 74
Table 91: Boise State University Pipeline Products and Ongoing Clinical Trials Overview 75
Table 92: Micro-RNA Based Diagnostic Test - Lung Cancer - Product Status 75
Table 93: Micro-RNA Based Diagnostic Test - Lung Cancer - Product Description 75
Table 94: Cancer Research Technology Limited Pipeline Products and Ongoing Clinical Trials Overview 76
Table 95: Biomarker Test - Lung Cancer - Product Status 76
Table 96: Biomarker Test - Lung Cancer - Product Description 76
Table 97: Cangen Biotechnologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 77
Table 98: Diagnostic Test - Early Stage Lung Cancer - Product Status 77
Table 99: Diagnostic Test - Early Stage Lung Cancer - Product Description 77
Table 100: Cangen Biotechnologies, Inc. - Ongoing Clinical Trials Overview 78
Table 101: Diagnostic Test - Early Stage Lung Cancer - Development Of An Early Stage Lung Cancer Diagnostic 79
Table 102: Celera Corporation Pipeline Products and Ongoing Clinical Trials Overview 80
Table 103: Lung Cancer Genotyping Assay - Product Status 81
Table 104: Lung Cancer Genotyping Assay - Product Description 81
Table 105: Cellanyx Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 82
Table 106: Cellanyx Test - Lung Cancer - Product Status 82
Table 107: Cellanyx Test - Lung Cancer - Product Description 82
Table 108: CellMax Life Pipeline Products and Ongoing Clinical Trials Overview 83
Table 109: Diagnostic Assay - Lung Cancer - Product Status 83
Table 110: Diagnostic Assay - Lung Cancer - Product Description 83
Table 111: CeMines, Inc. Pipeline Products and Ongoing Clinical Trials Overview 84
Table 112: CellCorrect LAb Test For Lung Cancer - Product Status 84
Table 113: CellCorrect LAb Test For Lung Cancer - Product Description 84
Table 114: Cepheid Pipeline Products and Ongoing Clinical Trials Overview 85
Table 115: Xpert OncoScreen Lung Cancer Assay - Product Status 85
Table 116: Xpert OncoScreen Lung Cancer Assay - Product Description 86
Table 117: Ceres Nanosciences, Inc. Pipeline Products and Ongoing Clinical Trials Overview 87
Table 118: Nanotrap Lung Cancer Biomarker Test - Product Status 87
Table 119: Nanotrap Lung Cancer Biomarker Test - Product Description 87
Table 120: Cernostics Inc. Pipeline Products and Ongoing Clinical Trials Overview 88
Table 121: TissueCypher Lung Cancer Test - Product Status 88
Table 122: TissueCypher Lung Cancer Test - Product Description 88
Table 123: ChemImage Corporation Pipeline Products and Ongoing Clinical Trials Overview 89
Table 124: Prognostic Test - Lung Cancer - Product Status 89

1.2 List of Figures
Figure 1: Lung Cancer - Pipeline Products by Stage of Development 20
Figure 2: Lung Cancer - Pipeline Products by Territory 21
Figure 3: Lung Cancer - Pipeline Products by Regulatory Path 22
Figure 4: Lung Cancer - Pipeline Products by Estimated Approval Date 23
Figure 5: Lung Cancer - Ongoing Clinical Trials 24

Companies Mentioned
AandG Pharmaceutical, Inc.
Abbott Diagnostics
Abcodia Ltd.
Aberystwyth University
Advanced Marker Discovery, S.L.
Advpharma Inc.
Almac Diagnostics Limited
Armune BioScience, Inc.
Biocept, Inc.
Biodesix Inc.
BioMark Diagnostics Inc.
BioMark Technologies Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

Market Access Impact: Non-Small Cell Lung Cancer (EU5) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

Prescription barriers hurt 5 of the 9 brands we surveyed. Is your brand losing market share? In the EU5, one of the most prescribed NSCLC drugs is stuck in 2nd place due to the biggest barrier-related ...

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

  • $ 5390
  • Industry report
  • September 2016
  • by Firstword Pharma

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s ...


Download Unlimited Documents from Trusted Public Sources

Pathology Statistics in the US and the UK

  • December 2016
    12 pages
  • Pathology  

    Digestive Syste...  

    Cancer  

  • United States  

    United Kingdom  

View report >

Pathology Statistics in the US and the UK

  • December 2016
    13 pages
  • Pathology  

    Digestive Syste...  

  • United States  

    United Kingdom  

View report >

Digestive System Disorder and Endocrine Disease Statistics in the US

  • December 2016
    4 pages
  • Digestive Syste...  

    Endocrine Disea...  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.